SCHEMBL20021987

SCHEMBL20021987

O=S(=O)(Nc1ccccc1)c1ccc2ccccc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.77
ATM Q13315 1/20 0.76
SMN1; SMN2 Q16637 3/20 0.74
LMNA P02545 2/20 0.74
KMT2A Q03164 6/20 0.69
MEN1 O00255 5/20 0.69
ALDH1A1 P00352 4/20 0.68
GAA P10253 1/20 0.68
PKM P14618 3/20 0.67
PKLR P30613 1/20 0.67
GPR27 Q9NS67 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
IL1RN P18510 1/20 0.62
KEAP1 Q14145 1/20 0.62
ERAP1 Q9NZ08 1/20 0.62
AKR1C3 P42330 1/20 0.61
MAPT P10636 2/20 0.61
PLAU P00749 3/20 0.60
MAPK1 P28482 1/20 0.60
HTT P42858 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28396503 1.00 PGR (0.77) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL29549847 1.00 PGR (0.77) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL9479593 0.93 PGR (0.73) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL9942091 0.86 ATM (0.68) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL808105 0.86 ATM (0.72) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL20021984 0.86 ATM (0.72) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL4556438 0.86 KMT2A (0.60) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL9942088 0.86 ATM (0.72) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL9465080 0.86 KMT2A (0.70) PGRATMSMN1; SMN2LMNAKMT2A
SCHEMBL10978762 0.86 KMT2A (0.60) PGRATMSMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111170905-B Synthetic method of sulfonamide compound 台州学院 2022-04-29 CN disclosed
CN-108822002-B Method for synthesizing N-aryl sulfonamide under assistance of ultrasonic waves 中南大学 2020-05-05 CN disclosed
CN-108822002-A A kind of method of ultrasonic wave added synthesis N- aryl sulfonic acid amides 中南大学 2018-11-16 CN disclosed
US-20180093960-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2018-04-05 US disclosed
US-20180093960-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2018-04-05 US disclosed
CN-101817767-A Substituted sulphonamide compound and preparation method, medicine composition and application thereof SHANGHAI INST BIOL SCIENCES 2010-09-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093960-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND LDLR, APOB, NR1H2 PGR 2048/4885ATM 2000/4885SMN1; SMN2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.